Breast Imaging

Why Is Routine Breast Cancer Screening Not Recommended for Average-Risk Men?

·
Why Is Routine Breast Cancer Screening Not Recommended for Average-Risk Men?

A 58-year-old man presents for his annual wellness visit. He has no specific complaints but mentions a friend was recently diagnosed with breast cancer and asks if he should get a “screening mammogram, just in case.” He has no family history of breast or ovarian cancer, no known genetic mutations, and a normal physical exam with no palpable breast lumps or skin changes. You are now faced with the clinical question of whether to order screening imaging for this average-risk, asymptomatic adult male. This article details the American College of Radiology (ACR) Appropriateness Criteria for this exact scenario, explaining the rationale for why routine imaging is not advised. For this presentation, all screening modalities, including mammography and ultrasound, are rated as `Usually not appropriate`.

Who Fits the ‘Average-Risk Male’ Breast Cancer Screening Scenario?

This guidance applies specifically to adult males who are considered to be at average risk for developing breast cancer. Correctly identifying these patients is the critical first step in applying the ACR recommendations. A patient fits this scenario if they are asymptomatic (no palpable lump, nipple discharge, or skin changes) and meet the criteria for average risk.

Inclusion criteria for this “average-risk” category include:

  • No personal history of breast cancer.
  • No known pathogenic genetic mutation that increases breast cancer risk (e.g., BRCA1, BRCA2, PALB2, CHEK2, ATM).
  • No significant family history, such as a first-degree relative (male or female) with breast cancer.
  • No history of radiation therapy to the chest between the ages of 10 and 30.
  • No underlying medical conditions known to significantly increase risk, such as Klinefelter syndrome, Cowden syndrome, or advanced liver disease (cirrhosis).

It is crucial to distinguish this scenario from others. This workflow does not apply if the patient is symptomatic (e.g., presents with a palpable mass), as that would necessitate a diagnostic workup, not a screening evaluation. Furthermore, this guidance is distinct from the approach for males at higher-than-average risk, who may have a genetic predisposition or strong family history that warrants a different screening strategy.

What Is the Rationale for Not Screening in This Scenario?

In an asymptomatic, average-risk male, the primary goal of screening would be to detect an occult, non-palpable malignancy. However, the clinical decision-making process is dominated by the extremely low prevalence of the disease in this specific population. Male breast cancer accounts for less than 1% of all breast cancers and less than 1% of all cancers in men. The lifetime risk for an average-risk man is approximately 1 in 833.

Because the pre-test probability of finding cancer is so low, the potential harms of screening—false positives, patient anxiety, unnecessary biopsies, and radiation exposure—far outweigh the potential benefits. A positive finding on a screening study is far more likely to be a false alarm or a benign entity than a true cancer.

The most common cause of male breast enlargement is gynecomastia, a benign proliferation of glandular tissue. This condition is extremely common and can mimic malignancy on imaging, leading to a high rate of false-positive results and subsequent invasive procedures. Other benign findings could include pseudogynecomastia (fat deposition), cysts, or lipomas. While invasive ductal carcinoma is the most common type of male breast cancer, its incidence in an unselected, average-risk population is too low to justify a population-based screening program.

Why Are All Imaging Studies ‘Usually Not Appropriate’ for This Presentation?

The ACR panel has concluded that for an average-risk adult male, no imaging modality is warranted for routine breast cancer screening. The rationale is rooted in the principles of evidence-based screening: the benefits must demonstrably outweigh the harms for the target population. For this group, they do not.

Mammography screening and Digital breast tomosynthesis (DBT) screening are both rated `Usually not appropriate`. While these are the cornerstones of screening for average-risk women, their use in men is problematic. The low incidence of disease means the positive predictive value of a screening mammogram is exceedingly low. This leads to a high number of false-positive results, triggering unnecessary biopsies for benign conditions like gynecomastia. Furthermore, both modalities involve ionizing radiation (Relative Radiation Level ☢☢ 0.1-1mSv), and exposing a large, low-risk population to this radiation is not justified without a clear mortality benefit, which has not been established in men.

US breast is also rated `Usually not appropriate` for screening in this context. Although it avoids ionizing radiation (Relative Radiation Level O 0 mSv), ultrasound has a high rate of false positives when used as a primary screening tool in low-prevalence populations. Its utility is in the diagnostic setting—for instance, to characterize a palpable lump found on clinical exam—not for screening asymptomatic men.

Other advanced modalities like MRI breast without and with IV contrast are similarly rated `Usually not appropriate`. MRI is highly sensitive but lacks specificity, resulting in an even higher false-positive rate than mammography. The cost, need for IV gadolinium-based contrast agents, and long exam times make it unsuitable for screening a population with such a low incidence of disease.

What’s Next? The Downstream Workflow Without Imaging

Since the recommended pathway is to forgo imaging, the downstream workflow focuses on clinical management, risk assessment, and patient education.

  • If No Imaging Is Performed (Recommended Path): The most appropriate next step is to educate the patient. Explain the rationale for not screening, emphasizing the low absolute risk and the high potential for false positives and unnecessary procedures. Counsel the patient on breast self-awareness, instructing them to report any new or persistent changes, such as a lump, skin dimpling, redness, or nipple discharge. Schedule routine annual clinical breast examinations as part of their regular health maintenance.
  • If Imaging Is Ordered Against Recommendations: If a screening study is performed and the result is negative (e.g., BI-RADS 1 or 2), the primary action is to provide reassurance and transition the patient back to the recommended clinical follow-up pathway. This result should not set a precedent for annual imaging. If the result is indeterminate or suspicious (e.g., BI-RADS 0, 3, 4, or 5), the patient is now on a diagnostic pathway that will likely require additional imaging and/or biopsy. This outcome exemplifies the primary harm the ACR guidelines aim to prevent: initiating an invasive and anxiety-provoking cascade for what is most likely a benign finding.

The key is to shift the focus from routine imaging to risk-appropriate surveillance and patient empowerment through education.

Pitfalls to Avoid (and When to Get Help)

Navigating this clinical scenario requires careful distinction between screening and diagnosis. The most significant pitfall is misclassifying the patient’s presentation or risk level.

  1. Confusing Screening with Diagnosis: Never apply this “no imaging” guidance to a man with a palpable breast lump, nipple discharge, or focal pain. A symptomatic patient requires a diagnostic workup, which typically starts with diagnostic mammography and/or targeted ultrasound.
  2. Inadequate Risk Assessment: Failing to take a thorough family history is a common error. Specifically ask about breast, ovarian, prostate, and pancreatic cancer in first- and second-degree relatives, as this may unmask a hereditary cancer syndrome (e.g., BRCA-related) that moves the patient into a high-risk category.
  3. Dismissing Patient Concerns: While screening is not recommended, a patient’s anxiety is real. Dismissing their concerns without a clear explanation can erode trust. A thoughtful conversation about the evidence is more effective than a simple refusal to order a test.

If you uncover a significant family history or genetic risk factor during your evaluation, consider a consultation with a genetic counselor or a referral to a high-risk breast clinic.

Related ACR Topics and Tools

This article covers a single, specific clinical variant. For a comprehensive overview of imaging recommendations across all male breast cancer screening scenarios, including for high-risk patients, please see our parent guide. For further research and workflow support, the following GigHz tools are available:

Frequently Asked Questions

If a man has gynecomastia, should he be screened for breast cancer?

No, gynecomastia itself is not an indication for routine cancer screening in an otherwise average-risk, asymptomatic man. Gynecomastia is a benign condition. If there is a new, firm, or eccentric lump within the breast tissue that is clinically suspicious, it should be evaluated with diagnostic imaging (mammography and/or ultrasound), not treated as a screening case.

Does this ‘no screening’ recommendation apply to older men, for example, over 70?

Yes, the American College of Radiology guidance for average-risk men does not specify an age cutoff. The recommendation against routine screening applies to all asymptomatic adult men at average risk, regardless of age, because the incidence remains too low to justify the harms of screening.

What if a patient insists on a screening mammogram despite the recommendation?

The best approach is a shared decision-making conversation. Reiterate the evidence: the very low chance of finding cancer, the high likelihood of a false positive, and the potential for unnecessary anxiety and biopsies. Document this conversation thoroughly. While patient autonomy is important, ordering a test that is ‘Usually not appropriate’ and may lead to harm should be done with extreme caution.

Is a clinical breast exam (CBE) recommended for average-risk men?

Yes, performing a clinical breast exam as part of a man’s annual physical examination is considered good practice. It provides an opportunity to detect palpable abnormalities and to educate the patient on breast self-awareness. A CBE is a clinical evaluation, not an imaging-based screening test.

If a man has a family history of prostate cancer, does that make him high-risk for breast cancer?

It depends. A single relative with prostate cancer may not significantly increase his risk. However, a strong family history of prostate cancer, particularly aggressive or metastatic disease, or a known family mutation in a gene like BRCA2, would indeed place him in a higher-than-average risk category where screening may be considered. This is why a detailed family history is essential.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026